Clinical Placement

Total Page:16

File Type:pdf, Size:1020Kb

Clinical Placement Acute Adult Speech and Language Therapy Clinical Placement Student Information Pack 2020/2021 **PLEASE NOTE THAT FROM SEPTEMBER 2020 THERE MAY BE MODIFICATIONS TO CLINICAL PLACEMENTS DURING THE COVID-19 PANDEMIC IN LINE WITH OUH TRUST AND NATIONAL POLICY. INDIVIDUAL STUDENTS WILL BE CONTACTED BY THERE DESGINATED PLACEMENT EDUCATOR TO DISCUSS EACH PLACEMENT BEFORE THEIR START DATE** 1 CONTENTS Departmental Information: Pages 3-8: NEUROSCIENCES DEPARTMENT Pages 9-10: ENT DEPARTMENT Pages 11-12: THE BLENHEIM HEAD AND NECK UNIT, CHURCHILL HOSPITAL Page 13: CHURCHILL HOSPITAL, OXFORD Pages 14-15: HORTON HOSPITAL, BANBURY Pages 14-17: JOHN RADCLIFFE HOSPITAL, OXFORD Page 18: EARLY SUPPORTED DISCHARGE FOR STROKE Pages 19-20: OXFORD CENTRE FOR ENABLEMENT (OCE) Pages 21-22: AAC SERVICE 2 NEUROSCIENCES DEPARTMENT, L2 WEST WING, JOHN RADCLIFFE HOSPITAL The S&LT Neurosciences Department is made up of a Highly Specialist Neurosciences Speech and Language Therapist and a Specialist Neurosciences Speech & Language Therapist forming 1.0wte. Claire McMahon (Highly Specialist SLT-Neurosciences) works Monday and Tuesday. Daniela Carrasco (Specialist SLT Neurosciences) works Tuesday – Friday (9.30am – 2.30pm). Our office is based in the Neurosciences Rehabilitation Department on Level 2 of the West Wing at the John Radcliffe Hospital and our direct line is 01865 231714. We can also be contacted via e-mail – [email protected] and [email protected] This placement may not be suitable for students with mobility issues, students are likely to be mobile, spending much of the day standing at bedside and walking between patient bed spaces across three floors. Lifts are available. A car is not essential. We offer an inpatient service to the Neurosciences ward and Neuro Intensive Care (NICU). The main ward is occupied by patients who have a range of neuro-medical and neurosurgical conditions (54 beds). We also have a high dependency unit (8 beds) providing a step down from NICU. Neuro Intensive Care is a separate 16 bedded ward. We also provide a service to the Neuro-Investigation ward, which is a 12 bedded day ward. In addition, we also provide input to SSIP ward (specialist surgery inpatients). This includes patients who have had plastics or ENT surgery input. 1. Neuromedical beds Patients may have neurological conditions such as Parkinson ’s disease, MND, Myasthenia Gravis, Lambert-Eaton Syndrome, Guillain-Barre Syndrome, Miller Fisher Syndrome, Multiple Sclerosis, Multiple Systems Atrophy, Dermatomyositis, Encephalitis, CVA, and Lateral Medullary Syndrome. 2. Neurosurgical beds Patients may have conditions such as cerebral tumours, aneurysms, acoustic neuromas, head injuries, subarachnoid haemorrhage, and subdural haematoma. These patients may have had surgical procedures, such as debulking of a tumour, ventricular drainage, coiling or clipping of an aneurysm, embolisation, and craniotomy. 3. Neuro-Intensive Care Unit (NICU). Patients on this ward may present with any of the above conditions and are acutely unwell. Often they will be on assisted ventilation and may have a tracheostomy. 3 SUMMARY OF CONDITIONS / DISORDERS The following summarises the neurology of the more common disorders that you may see whilst on placement. You may want to familiarise yourself with the speech, language and swallowing aspects of some of these disorders. Neuromedical Myasthenia Gravis is the most common primary disorder of neuromuscular transmission. The usual cause is an acquired immunological abnormality, but some cases result from genetic abnormalities in the Neuromuscular Junction (NMJ). In MG, the neurotransmitter Acetylcholine (the chemical that transmits impulses between nerves and muscles) is blocked by antibodies to its receptor. Patients present with limb weakness, ptosis or diplopia, aphonia, dysarthria and dysphagia. Symptoms become worse with prolonged muscle movement. Lambert-Eaton Syndrome (myasthenic syndrome) is a disorder with symptoms very similar to those of Myasthenia Gravis. There is muscle weakness associated with disturbed communication between nerves and muscles. In Lambert-Eaton Syndrome, the distortion is caused by an insufficient release of neurotransmitter by the nerve cell. As muscle contraction continues, the amount of neurotransmitter may build up in sufficient quantities and result in increased strength. Therefore, clinically, MG results in weaker muscle movement with continued use, and LEMS in stronger muscle movement. Multiple Sclerosis – The central nervous system becomes inflamed and destroyed by the patient’s own immune system in a process called demyelination, which usually starts in adult life. There are three different patterns: relapsing/remitting MS (80% show this pattern), secondary progressive MS (follows on from the relapsing/remitting type in 50% of cases within 10 years. Recovery from relapses is incomplete, and the relapsing pattern is progressively lost.) Primary progressive MS occurs in 10-15% of patients. Symptoms do not remit and progressively worsen with time from the onset of the condition. Symptoms include pain, fatigue, bowel and bladder problems, spasticity, depression (36%), anxiety (25%). We are asked to see MS patients with speech and swallowing problems, but have also encountered language disorders in this client group. Gullian-Barre Syndrome is an acute inflammatory demyelinating disorder that affects the peripheral nerves, sympathetic and parasympathetic nerves. 50-70% of GBS patients have had a recent viral or bacterial infection. It is an auto-immune disease. That is, the body’s own immune system begins to attack the body itself. In GBS, motor weakness of more than one limb occurs progressively over days to six weeks. Recovery takes weeks to months. Miller Fisher Syndrome is a variant of GBS, and is characterised by abnormal muscle coordination (ataxia), opthalmoplegia (paralysis of eye muscles) and absence of reflexes. Motor Neurone Disease is a progressive condition characterised by degeneration of motor neurones in the cortex and the anterior horns of the spinal cord, and degeneration of cranial nerve nuclei within the brainstem. Sensation is preserved in people with MND. Different terms are often used to describe involvement at each level of the CNS . • Amyotrophic Lateral Sclerosis (ALS) accounts for 66% of cases, and is a mixture of both upper and lower motor neurone involvement. It is characterised by muscle weakness, spasticity, hyperactive reflexes and emotional liability. • Progressive Bulbar Palsy (PBP) (25% of cases) degenerates the nerves that control speech and swallowing. 4 • Progressive Muscular Atrophy (PMA) affects mainly the lower motor neurones, and is characterised by muscle wasting and weakness, loss of weight and muscle twitching. • Primary Lateral Sclerosis (PLS) affects primarily the upper motor neurones, resulting in stiffness and spastic paralysis of the limbs. Parkinson’s Disease occurs when certain nerve cells in the part of the brain called the substantia nigra die or become impaired. Normally, these cells produce a vital chemical known as dopamine. Dopamine allows smooth function of the body’s muscles and movement. The loss of dopamine production in the brain causes the primary symptoms of the disease. These are tremor, slowness of movement (bradykinesia), rigidity, and difficulty with balance. They present with hypokinetic dysarthria and dysphagia. Multiple Systems Atrophy refers to three slowly progressive related disorders that affect the central and autonomic nervous system. There is a life expectancy of 10 years or less, and it is usually diagnosed in people over 50. Olivopontocerebellar atrophy affects balance, coordination and speech. Striatonigrad degeneration is a parkinsonian form, characterised by slow movement and stiff muscles. MSA with orthostatic hypertension (formerly Shy-Drager syndrome)is a form with predominant autonomic system involvement. In all three forms of MSA, the patient can have orthostatic or postural hypotension (an excessive drop in blood pressure when the patient stands up, causing dizziness or momentary blackouts). Other symptoms include stiffness, rigidity, loss of balance/coordination, impaired speech, breathing and swallowing problems, blurred vision, impotence, constipation and urinary difficulties. Most patients develop dementia in the late stages of the disease. There is no specific treatment. (National Institute of Neurological Disorders and Stroke) Dermatomyositis is thought to be an autoimmune disease, meaning that the body’s immune system, which normally fights infections and viruses, does not stop fighting once the infection has gone. It is more common in women, and can occur at any age. It presents as a rash which looks patchy, reddish or purple. Some people also have hardened bumps under the skin. Muscle weakness usually happens over a period of days, and begins with muscles that are closest to and within the trunk of the body, e.g. neck, hip, shoulders. Some DM patients have dysphagia. Patients are treated with Prednisone, which is a steroid, to stop the body from attacking the muscles by slowing down the immune system. (The Myositis Association website) Acoustic Neuromas are benign tumours of the 8th cranial nerve. Symptoms include hearing loss, tinnitus and imbalance. Treatment is either microsurgery aimed at complete removal of the tumour, or Gamma knife surgery, a radiosurgery technique to shrink the tumour over time. Microsurgery may result in hearing loss on the affected side, and 1 in 5 patients
Recommended publications
  • YOUNG PERSON with HAEMOPHILIA (12-15Yrs) PARTICIPANT INFORMATION SHEET
    [Emi + Me Young Persons with Haemophilia PIS (12-15yrs) v7 Dated 16 April 2020: IRAS number 248511] Oxford Haemophilia & Thrombosis Centre Churchill Hospital Old Road Headington Oxford OX3 7LE YOUNG PERSON WITH HAEMOPHILIA (12-15yrs) PARTICIPANT INFORMATION SHEET Study Title: Emi and Me: An Exploration of Emicizumab on the lives of people with haemophilia and inhibitors and their families Study Sponsor: Haemnet Protocol Number: Version 4 dated 26 November 2019 Principal Investigator: Simon Fletcher Co-investigators: Dr Kate Khair, Luke Pembroke Introduction This study is talking to people about what it is like to use Emicizumab (Hemlibra®) in people with haemophilia and inhibitors. We also want to find out about impact of Emicizumab use on the lives of your close family members (parents and sisters). We will get this information through talking to you all. The study will also form part of a body of work given as evidence for a PhD currently being undertaken by the Principal Investigator Please read this information carefully and talk to your mum, dad, carer or hospital haemophilia team if you have any questions. Please ask us if there is anything that is not clear or if you would like more information, our contact details are at the end of this information sheet. If you don’t want to take part that is fine. Why are we doing this study? From this study we want to find out what it is like to use Emicizumab for you and your close family members. We also want to understand what you think about your haemophilia care now and how it might be in the future.
    [Show full text]
  • Risk of Infection
    Adapted from Oxford Radcliffe Hospitals NHS Trust Cancer Care and ‘Risk of Infection, Information sheet’ Clinical Haematology Department, Cancer and Haematology Centre Haematology Service Churchill Hospital, Oxford Risk of Infection How can I help reduce healthcare associated infections? Infection control is important to the well-being of our patients and for that reason we have infection control procedures in place. Keeping your hands clean is an effective way of preventing the spread of infections. We ask that you, and anyone visiting you, use the hand rub (special gel) available at the main entrance of the hospital and at the entrance to every ward before coming in to and after leaving the ward or Important information for all patients hospital. In some situations hands may need to be washed at the sink using soap and water rather than using the hand If you require an interpreter or need a document in another rub. Staff will let you know if this is the case. language, large print, Braille or audio version please ask for assistance. www.buckshealthcare.nhs.uk Author: Haematology Leaflet code: CISS - 122 Issue date: January 2015 Version: 2 Reviewed: January 2017 Review date: January 2019 How to contact us When you have been diagnosed with a condition that affects your bone marrow or lymph glands, you are much Emergency Phone No. more at risk of infection than a member of the general public. This risk is high because it is much more difficult for Oncology/Haematology CCHU you to fight infections. Stoke Mandeville Hospital This can be a very serious situation so needs to be (Monday – Friday 9.00am – 5.00pm) acted on immediately.
    [Show full text]
  • Locality Place Based Primary Care Plan: North East Oxfordshire Locality
    Locality Place Based Primary Care Plan: North East Oxfordshire Locality North East Oxfordshire Locality Place Based Plan Page 1 of 53 January 2018 Contents Foreword ............................................................................................................................................................................................................ 4 North East Locality Plan Executive Summary ................................................................................................................................................. 5 Part A: Introduction: Approach to developing the plan for North East Oxfordshire ..................................................................................... 6 1. The purpose of this locality place based plan ............................................................................................................................................ 6 2. Who helped to inform our plan? ................................................................................................................................................................. 7 Part B: The demographics of the North East Oxfordshire population ........................................................................................................... 9 1. Summary ................................................................................................................................................................................................... 9 2. The health of our community in North East Oxfordshire
    [Show full text]
  • Director of Infection Prevention and Control (DIPC) Annual Report 2017/18
    Trust Board Meeting in Public: Wednesday 12 September 2018 TB2018.84 Title Director of Infection Prevention and Control (DIPC) Annual Report 2017/18 Status For information History Previously presented at Hospital Infection Prevention and Control Committee (HIPCC) Board Lead(s) Dr Tony Berendt Key purpose Strategy Assurance Policy Performance TB2018.84 Infection Prevention & Control Annual Report 2017/18 Page 1 of 32 Oxford University Hospitals NHS Foundation Trust TB2018.84 Figure 1: A graphical summary of key events in infection control activity in 2017-18 TB2018.84 Infection Prevention & Control Annual Report 2017/18 Oxford University Hospitals NHS Foundation Trust TB2018.84 Executive Summary 1. The annual report of the Director of Infection Prevention and Control (DIPC) is a mandated report to the Board that describes the structure and key activities of the infection prevention and control (IPC) team. These activities include surveillance, outbreak investigation and management, audit, and teaching and training. 2. Methicillin-resistant Staphylococcus aureus (MRSA) Bacteraemia Zero avoidable MRSA bacteraemias are permitted by national mandate. There was one unavoidable post-48 hour bacteraemia in 2017/18, and no avoidable bacteraemias. There were 3 pre-48 hour cases of MRSA bacteraemia, considered to represent the development of infection prior to hospitalisation. 3. Clostridium difficile There were 72 OUH apportioned cases identified after three days of admission for 2017/2018 against an upper set limit of 69. 4. Methicillin-sensitive Staphylococcus aureus (MSSA) Bacteraemia There were a total of 36 incidents of post-48 hour MSSA bacteraemia, a lower figure than the 41 cases last year. 5. Gram negative blood stream Infections (GNSBI) April 2017 saw the introduction of additional nationally mandated GNBSI surveillance.
    [Show full text]
  • It's Not Just a Walk in the Park !
    It’s Not Just a Walk in the Park ! BACK BY POPULAR DEMAND and this time it really isn’t a Walk in the Park! 5 mile sponsored walk supporting your Hospital Charity Sunday 5 October 2014 10.30am You decide which Ward or Department you would like to support! Oxford Radcliffe Hospitals Charitable Funds and Oxford Health Charitable Funds Support Your Hospital Charity Route Map About the event Sunday 5 October 2014 10.30am It’s Not Just A Walk In The Park is back by popular demand and this time it really isn’t a walk in the park! New for 2014 our sponsored 5 mile walk route will take in three of the four Oxford University Hospital sites and the Warneford Hospital as, after all, the event is about raising Johnmuch neededRadcliffe funds Hospital. Churchill Hospital. Nuffield Orthopaedic Centre. for the hospitals and you will be able to specify exactly whichHorton Fund, ward General or Hospital. John Radcliffe Hospital. Churchill Hospital. Nuffield department you would like to support. Orthopaedic Centre. Horton General Hospital. John Radcliffe Hospital. It might be a ward that you or a loved one has been treated in andChurchill this will Hospital. Nuffield Orthopaedic Centre. Horton General Hospital. be your way of saying ‘thank you’ along with your family and friends. JohnIf you Radcliffe Hospital. Churchill Hospital. Nuffield Orthopaedic Centre. are unsure of the name of the Fund you would like to support please callHorton the General Hospital. John Radcliffe Hospital. Churchill Hospital. Nuffield Fundraising Office on 01865 743444 or email at [email protected] and we will be happy to identify the correct Fund for you.
    [Show full text]
  • Water Eaton Park & Ride
    Water Eaton Park & Ride Sat-Nav users enter postcode OX2 8HA for Water Eaton. • Service 500 to City Centre & Summertown • Service 700 to Churchill Hospital, Headington, John Radcliffe Hospital & Summertown • Service 700 to Kidlington • Journey time to city is around 15 minutes • Journey time to John Radcliffe Hospital is around 15 minutes • 798 parking spaces in total • 40 disabled car parking spaces • Entry barrier height 2.1m but spaces for up to 7 high sided vehicles when security patrols are on duty. • Modern waiting room with toilets & RT info display • Free car parking for up to 72 hours. • On site security patrol between 0700 and 1930. • No service on Sundays Water Eaton Park & Ride First buses from Water Eaton Park & Ride Destination Service Mon-Fri Sat Sun City Centre 500 0700 0700 No service Churchill / JR Hospital 700 0631 No service No service Last buses to Water Eaton Park & Ride Departure point Service Mon-Fri Sat Sun City Centre 500 2348* 2348* No service Churchill Hospital 700 1905 No service No service Service frequency from Water Eaton Park & Ride Destination Service Mon-Fri Sat Sun City Centre 500 15 mins 15 mins No service Churchill or JR Hospitals 700 15 mins No service No service * Return buses to Water Eaton after 19:05 are operated by local bus services 2A which stop on the main road outside the park & ride site. Park & ride fares 500 700 Peak return (before 9am Mon-Fri) £2.50 Day return fare £2.20 Off peak return (all other 1 week multi-ride times) £2.20 ticket £15.00* 2 person peak return £4.50 1 week multi-ride ticket £55.00* 2 person off peak return £4.00 12 journey ticket £12.50 1 year season £391* (discounts ticket (Hospital available for 1 year season ticket £300 Routes only) NHS staff) Prices / times quoted correct to July 2009 but may be subject to change.
    [Show full text]
  • Annual Report 2006 2
    1. Oxford Radcliffe Hospitals NHS Trust Annual Review 2006 Annual Report 2006 2. Oxford Radcliffe Hospitals NHS Trust Annual Review 2006 Foreword Sir William Stubbs, Chairman The Oxford Radcliffe Hospitals NHS Trust efficient journey through their treatment. (ORH) has an international reputation for By improving our performance in this way clinical excellence and in recent years the and removing bottlenecks and duplication Trust has been able to improve its facilities we will not only enhance patients’ and efficiency to match and support this experience, we will reduce costs. This reputation. work is an obvious extension of the macro- view provided by the Strategic Review of This has taken us from being a no-star our services that we have been undertaking trust, with costs above the average, to over the past two years. a two-star trust that is among the most efficient Trusts in England. This journey has The task ahead is not a small one, meant reduced waiting times, improved but it is achievable, particularly with diagnostic equipment, new services and the extraordinary dedication and new and improved infrastructure. resourcefulness of our staff. Despite this exemplary performance we Despite the challenging times of the past and beyond, with state-of-the-art cancer are, however, in a position where the year, we have had the pleasure of seeing the services. A particularly important element county’s funding levels have for some time new Oxford Children’s Hospital and new of the Private Finance deal that has not matched the levels of demand - and West Wing nearing completion on the John made this project possible is the built- this meant that last year we received £12.4 Radcliffe site.
    [Show full text]
  • Global Atlas of Palliative Care at the End of Life
    Global Atlas of Palliative Care at the End of Life January 2014 Acknowledgements and authorship Edited by: Stephen R. Connor, PhD, Senior Fellow to the Worldwide Palliative Care Alliance (WPCA). Maria Cecilia Sepulveda Bermedo, MD, Senior Adviser Cancer Control, Chronic Diseases Prevention and Management, Chronic Diseases and Health Promotion, World Health Organization. The views expressed in this publication do not necessarily represent the decisions, policy or views of the World Health Organization. This publication was supported in part by a grant from the Open Society Foundations’ International Palliative Care Initiative. Special thanks to Mary Callaway and Dr Kathleen Foley. Contributing writers: Sharon Baxter, MSW, Canadian Hospice Palliative Care Association, Canada Samira K. Beckwith, ACSW, LCSW, FACHE, Hope Hospice, Ft Myers, FL, USA David Clark, PhD – University of Glasgow, Scotland James Cleary, MD – Pain and Policies Study Group, Madison, WI, USA Dennis Falzon, MD – WHO Global TB Program, WHO Geneva Philippe Glaziou, MD, MPhil, Dip Stat – WHO Global TB Program, WHO Geneva Peter Holliday, St. Giles Hospice, Litchfield, England Ernesto Jaramillo, MD – WHO Global TB Program, WHO Geneva Eric L. Krakauer, MD, PhD – Harvard Medical School Center for Palliative Care, Boston, MA, USA Suresh Kumar, MD – Neighborhood Network in Palliative Care, Kerala, India Diederik Lohman – Human Rights Watch, New York, USA Thomas Lynch, PhD – International Observatory for End of Life Care, Lancaster, England Paul Z. Mmbando (MBChB, MPH, DrH) Evangelical Lutheran Church, Arusha, Tanzania Claire Morris, Worldwide Palliative Care Alliance, London, England Daniela Mosoiu, MD – Hospice Casa Sperantei, Brasov, Romania Fliss Murtagh FRCP PhD MRCGP, Cicely Saunders Institute, Kings College London Roberto Wenk, MD – Programa Argentino de Medicina Paliativa Fundación, Argentina In addition, the editors would like to thank the following: All WHO collaborating centres on palliative care (see appendix for details) Ricardo X.
    [Show full text]
  • Oxford Medicine
    Oxford Medicine THE NEWSLETTER OF THE OXFORD MEDICAL ALUMNI OXFORD MEDICINE • DECEMBER 2019 Courtesy of Ludwig Cancer Research of Ludwig Cancer Courtesy The Regius Professor Sir Tingewick is Does reflects on Peter Ratcliffe 80! Developmental 45 years in FRS, Nobel Dyslexia Really medicine Laureate Exist? 2 / OXFORD MEDICINE DECEMBER 2019 President’s Piece Welcome to the December Sir William Osler’s Centenary commemorations will issue of Oxford Medicine, the continue throughout the year in Oxford and beyond. newsletter for Oxford Medical The Osler Club is the first of a number of thriving Alumni (OMA) who have postgraduate Oxford medical societies we plan to feature. trained, taught, or worked at Professor Terence Ryan summarises this year’s five Osler Oxford. Professor John Morris, Club seminars exploring the Oslerian theme ‘For Health OMA president for the past and Wellbeing, Science and Humanities are one’. six years, handed the baton Tingewick is 80 this year. In 2019, as in 1939, Tingewick to me in September. It is a Dr Lyn Williamson, is still the most inclusive Oxford clinical student society. OMA President daunting task to take over from This year, every first year clinical student took part - someone so beloved and so that is 165! The show was a triumph of teamwork and respected, who has taught anatomy to generations talent. The legacy of camaraderie will last a lifetime - as of Oxford students and postgraduates, and shaped witnessed by the 80th anniversary celebrations. Dr Derek the preclinical school for many years. With his Roskell, Senior Tingewick Member for 25 years adds his characteristic kindness and wisdom, he said: ‘You will be fine - and I will be there to advise you’.
    [Show full text]
  • Speciality Training Infectious Diseases with Microbiology Or
    Speciality Training Infectious Diseases with Microbiology or General (Internal) Medicine Training Programme Director: Dr Bridget Atkins Trainee Representative: Dr Elham Khatamsaz Introduction ID/micro is currently a six year training programme with 12 months credit allowed if trainees obtain separate research funding during a period out of programme (OOPR). ID/GIM is a five year programme. In August 2015 a new combined infection training programme will be introduced subject to GMC approval. This will constitute 2 years of core infection training followed by either 2 years of Medical Microbiology (MM), Medical Virology (MV) or Infectious Diseases (ID) or 3 years to obtain a CCT in ID/MM or ID/MV or ID/GIM. In Oxford the programme offers training for a CCT in ID/Micro or ID/GIM. Entry is at ST3 level after achievement of Core Medical Training and MRCP (or equivalent). Trainees currently enter on the 2010 Med Micro (RCPath) and Infectious Diseases (RCP) curricula and are required to fulfil the work competencies, work placed based assessments and knowledge based assessments for both. Trainees in 2015 will be required to be on the latest curriculum which will be the new combined infection training (CIT) and relevant Higher Specialist training (HST) programme as above. Those doing general internal medicine with ID will need to fulfil the requirement of the RCP GIM curriculum. Trainees will undergo posts in microbiology/virology (in Oxford and/or Aylesbury), infection consults, infectious diseases ward, bone infection unit and GIM/ID (Oxford and/or Slough). The deanery collaborates with Wessex deanery and opportunities exist for delivery of ID in Southampton too.
    [Show full text]
  • Advanced Practice in Endocrinology Nursing Sofia Llahana · Cecilia Follin Christine Yedinak · Ashley Grossman Editors
    Advanced Practice in Endocrinology Nursing Sofia Llahana · Cecilia Follin Christine Yedinak · Ashley Grossman Editors Advanced Practice in Endocrinology Nursing With Paediatric Editors Kate Davies and Margaret F. Keil Editors Sofia Llahana Cecilia Follin School of Health Sciences, City Department of Oncology University of London Skåne University Hospital London Lund UK Sweden Christine Yedinak Ashley Grossman Northwest Pituitary Center Churchill Hospital Oregon Health and Sciences University University of Oxford Portland, OR Oxford USA UK ISBN 978-3-319-99815-2 ISBN 978-3-319-99817-6 (eBook) https://doi.org/10.1007/978-3-319-99817-6 Library of Congress Control Number: 2018968596 © Springer Nature Switzerland AG 2019, Corrected Publication 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]
  • Celebrating 13 Decades of Nurse Education 125 YEARS of NURSE EDUCATION in OXFORD
    Celebrating 13 decades of nurse education 125 YEARS OF NURSE EDUCATION IN OXFORD Welcome to the 125 Years of Nurse Education in Oxford celebration booklet ACKNOWLEDGEMENTS We wish to thank the following This booklet details the last 13 decades of nurse people or organisations for their education in Oxford and Swindon. We are grateful help in compiling this booklet: to the people who have taken time to share their experiences of nurse education. DESIGNER ■ Flora Hands, Carline Creative The training and education of health care professionals has long been a cornerstone of life in Oxford and in AUTHORS the 20th and 21st Centuries Oxford Brookes University ■ Xante Cummings has played its own vital role in working with local ■ Annie Thompson-Lynch partners to provide professional healthcare education. ■ Dr Liz Westcott Nurse training in Oxford can trace its beginnings back to 1782. Then a non-regulated training, the early THE RADCLIFFE GUILD OF NURSES – beginnings of a formal nurse education, started in 1891 PERSONAL REMINISCENCES FROM: at the Radcliffe Infirmary on Woodstock Road. ■ Rita Bayley The records, many of which we have accessed to write ■ Theresa Bentley this booklet, provide a fascinating history. Between ■ Sue Bradshaw 1921 and 1991, 7948 nurses’ names were recorded. ■ Nurse training continued at the Radcliffe Infirmary and Nicky Brennan in 1979 the John Radcliffe 2 site was opened and the ■ Anne Carter ‘The School of Nursing’ transferred to this new site. ■ Mary Campbell In the mid 1980s Malcolm Ross, then Chief Nursing ■ Mary Dickman Officer in Oxford, Pam Jones the Head of Nursing ■ June Fisher Education in Oxford entered into discussions with ■ Eileen Forbes the then Vice Chancellor, Clive Booth and senior staff ■ at Oxford Polytechnic.
    [Show full text]